EUCTR2011-005535-68-GB进行中（未招募）不适用
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent must be performed before any assessment is performed for Period I
- •- Male and female subjects ages at least 18 years of age
- •- Fasting TG = 8.4 mmol/L (750 mg/dL) at Screening
- •- An established diagnosis of Familial Chylomicronemia Syndrome (HLP Type I) confirmed through ultracentrifugation or by documented medical history of a fasting TG = 8.4 mmol/L (750 mg/dL) and by documentation of any of the following at Screening Period:
- •a. Confirmed homozygote or compound heterozygote for known loss-of-function mutations in Type I-causing genes (such as LPL, apoCII, GPIHBP1 or LMF1)
- •b. Post heparin plasma LPL activity of = 20% of normal
- •c. Confirmed presence of LPL inactivarting antibodies
- •-History of pancreatitis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Although a history of pancreatitis is required, this must be inactive for at least 1 week prior to Screening Visit
- •- Treatment with fish oil preparations within 4 weeks prior to randomization
- •- Treatment with bile acid binding resins (i.e., colesevelam, etc) within 4 weeks prior to randomization
- •- Treatment with fibrates within 4 weeks prior to randomization
- •- Glybera [alipogene tiparvovec (AAV1-LPLS447X)] gene therapy exposure within two years prior to screening
- •- History of malignancy of any organ system (other than localised basal cell carcinoma of the skin), treated or untreated, within the past 1 year, regardless of whether there is evidence of local recurrence or metastases.
- •- Any surgical or medical conditions, acute or unstable chronic disease which may, based on investigators opinion, jeopardize the patient in case of participation in the study or might significantly alter the absorption, distribution, metabolism or excretion of the study drug. History of drug or alcohol abuse within the 12 months prior to randomization or evidence of such abuse at screening. Evidence of liver disease or liver injury as indicated by abnormal liver function tests such as AST or ALT, or serum bilirubin.
- •- Use of any other investigational drugs at the time of screening, or within 30 days or 5 half-lives of enrollment, whichever is longer
- •-eGFR < 30ml/min/1.73m2 or history of chronic renal disease
- •- Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer of required by local regulations or any other limitation of participation based on local regulations
- •- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- •- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG positive laboratory test.
- •- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 100 days after discontinuation of investigational study drug.
研究者
相似试验
尚未招募
3 期
A randomized, double-blind, placebo controlled studyassessing the long-term effect of dupilumab on preventionof lung function decline in patients with uncontrolledmoderate to severe asthmaJ45 NULLPER-009-23sanofi-aventis Recherche & Development
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia SyndromeEUCTR2011-005535-68-NLovartis Pharma Services AG42
招募中
1 期
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Severe AsthmaAsthmaMedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2024-513423-16-00Sanofi-Aventis Recherche & Developpement3,820
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in patients with Hereditary Periodic FeversEUCTR2013-004291-35-IEovartis Pharma Services AG180
已完成
3 期
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia SyndromeFamilial Chylomicronemia Syndrome10013317NL-OMON39328ovartis4